相关实验视频
Updated: Feb 19, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
977
阿尔茨海默病:关于诊断和治疗的临床更新
Dror Shir1, Christian Lachner2,3
1Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States.
Neurologia i neurochirurgia polska
|February 17, 2026
概括
这就是阿尔茨海默病的原因.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 痴呆症研究 痴呆症研究
背景情况:
- 阿尔茨海默病 (AD) 是痴呆的主要原因,其特征是认知能力下降.
- 人口老龄化正在增加阿尔茨海默病的患病率,给医疗保健系统带来压力.
- 了解AD病理生理学和生物标志物对于诊断和治疗至关重要.
研究的目的:
- 审查当前的阿尔茨海默病诊断框架.
- 讨论在AD诊断和治疗中的挑战和机遇.
- 探索生物标志物和新疗法在临床实践中的整合.
主要方法:
- 分析当前的诊断框架,包括临床评估和生物标志物.
- 复习先进的成像和流体生物标记分析.
- 对抗粉样蛋白单克隆抗体疗法的评估及其实施挑战.
主要成果:
- 生物标志物集成需要平衡准确性与实际考虑.
- 共同决策对于治疗选择至关重要.
- 抗粉样蛋白疗法和针对陶的研究显示出有前途.
结论:
- 整合生物标志物测试需要对患者进行仔细的风险效益分析.
- 可扩展的,非侵入性的生物标志物可以改变诊断工作流程.
- 多学科合作是桥梁研究和临床实践的关键.
相关概念视频
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Dementia
591
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
591
Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Atherosclerosis III: Management
460
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460

